It is conceivable that BACE1 inhibitors may have dual beneficial mechanisms to halt or slow AD progression at the early stage not only by reducing brain Aβ production but also by directly alleviating insulin resistance in the CNS and periphery (Figure 1). Here, BACE1 is linked to Alzheimer disease.